Trials / Recruiting
RecruitingNCT06195267
Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI)
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 500 (estimated)
- Sponsor
- Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with cardiovascular diseases. Therefore, the prevention of SIRS and MODS is of great clinical value, and immunomodulatory therapy with sivelestat may be beneficial. This study was designed to test the hypothesis that the administration of sivelestat during the acute phase of cardiovascular diseases will result in a reduced incidence of SIRS and MODS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sivelestat | The total 24-hour dose of Sivelestat sodium (4.8mg/kg) was dissolved with 50 ml normal saline. The drug flow rate was set at 2ml/h with an intravenous microinfusion pump, and the constant speed infusion was completed in 24h. |
| DRUG | Blank control | Patients only received standard treatment and care. |
Timeline
- Start date
- 2024-07-01
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2024-01-08
- Last updated
- 2024-11-22
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06195267. Inclusion in this directory is not an endorsement.